Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 83,839 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Not yet recruiting Not applicable Interventional

The Impact of Brief Behavioral Treatment for Insomnia Versus Brief Mindfulness Treatment on Cognition and Sleep Health in Adults (Age 50+) With HIV

NCT07272863
View directory record Official record
Conditions
Insomnia, Cognition, Aging, HIV
Interventions
BBTI, BMT
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
50 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 4 Interventional Results available

Dutasteride for the Reduction of Alcohol Use in Male Drinkers

NCT01262287
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 2 Interventional

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

NCT01472887
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
SAR3419
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Augusta, Georgia • Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 21, 2026, 6:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Investigational TMS Treatment for Depression

NCT03175887
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
TMS
Device
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-2, Myelodysplastic Syndrome
Interventions
Azacitidine, Glutaminase Inhibitor CB-839
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 21, 2026, 6:38 PM EDT
Recruiting Not applicable Interventional

Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations

NCT07179016
View directory record Official record
Conditions
Chronic Pain (Back / Neck), Chronic Pain Management, Chronic Knee Pain, Joint Pain
Interventions
Auricular Point Acupressure (APA) - Self Management (SM), Education Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Columbia, South Carolina • Fort Worth, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 6:38 PM EDT
Completed No phase listed Observational

Resynchronization Therapy in Young Patients With and Without CHD

NCT00208806
View directory record Official record
Conditions
Dilated Cardiomyopathy, Pediatric
Interventions
congestive heart failure patients
Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

NCT00134004
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 74 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

NCT02370784
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

NCT00556452
View directory record Official record
Conditions
Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
Drug · Procedure · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Recruiting Phase 2 Interventional

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Biospecimen Collection, Prasterone, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

NCT00719849
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 6:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

NCT04624633
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Umbralisib, Ublituximab
Drug
Lead sponsor
Jennifer R. Brown, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Terminated Phase 1 Interventional

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

NCT03940352
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions
HDM201, MBG453, Venetoclax
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 21, 2026, 6:38 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment

NCT07742449
View directory record Official record
Conditions
Cancer, Pain, Pain Management, Chronic Pain, American Indian or Alaska Native
Interventions
Empowered Relief
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949
View directory record Official record
Conditions
Smoking Cessation
Interventions
Cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Not applicable Interventional

Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression

NCT01441258
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
Dialectical Behavior Therapy Skills (DBT-S) Groups, Wait List-Treatment as Usual, No intervention-treatment as usual
Behavioral
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 21, 2026, 6:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking

NCT01359709
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Nicotine polacrilex
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 21, 2026, 6:38 PM EDT
Not listed Not applicable Interventional

Hear Me Read 2021 Clinical Trial

NCT05245799
View directory record Official record
Conditions
Hearing Loss, Deafness, Hearing Disorders in Children, Hearing Impaired Children, Speech Therapy, Speech Disorders in Children, Literacy
Interventions
Speech Language Therapy, Digital Software Application
Behavioral
Lead sponsor
Prasanth Pattisapu
Other
Eligibility
3 Years to 5 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 21, 2026, 6:38 PM EDT
Not yet recruiting Phase 1 Interventional

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07221032
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose), Daratumumab 16 mg/kg
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 6:38 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 21, 2026, 6:38 PM EDT